Skip Navigation

European Heart Journal 2004 25(13):1179-1180; doi:10.1016/j.ehj.2004.01.027
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hanefeld, M.G
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hanefeld, M.G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letter to the Editor

Meta-analysis of long-term studies to assess the effect of acarbose on cardiovascular risk reduction – scientifically credible: Reply

M.G Hanefeld*

Zentrum fur Klinische Studien, Fiedlerstr. 34, GWT, TU Dresden, Dresden 01307, Germany

* Tel.: +49-351-4400-580; fax: +49-351-4400-581
E-mail address: hanefeld@gwt-tud.de

The first 10% of the full text of this article appears below.

The authors criticised our meta-analysis of seven long-term studies to assess the effect of acarbose on cardiovascular risk reduction. Two different approaches are generally accepted as standard procedures for meta-analyses.1 These are systematic literature reviews or meta-analyses of all randomised controlled trials. Our meta-analysis is based on the latter approach. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CMAJHome page
J. McCormack, K. Johns, and H. Tildesley
Metformin's contraindications should be contraindicated
Can. Med. Assoc. J., August 30, 2005; 173(5): 502 - 504.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Hanefeld, R. G. Josse, and J.-L. Chiasson
{alpha}-Glucosidase Inhibitors for Patients With Type 2 Diabetes: Response to van de Laar et al.
Diabetes Care, July 1, 2005; 28(7): 1840 - 1840.
[Full Text] [PDF]